Guerbet S. A. (GBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guerbet S. A. (GBT) has a cash flow conversion efficiency ratio of 0.188x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€48.81 Million ≈ $57.07 Million USD) by net assets (€260.08 Million ≈ $304.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Guerbet S. A. balance sheet independence to measure how much of total assets are equity-financed.
Guerbet S. A. - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Guerbet S. A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Guerbet S. A. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Guerbet S. A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guerbet S. A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tata Steel (Thailand) Public Company Limited
F:MVX
|
0.049x |
|
Nicolas Correa SA
MC:NEA
|
0.073x |
|
CHINA NEW CITY COMM.
F:C7B
|
N/A |
|
The Joint Corp
NASDAQ:JYNT
|
-0.095x |
|
Fonar Corporation
NASDAQ:FONR
|
0.001x |
|
Menang Corporation (Malaysia) Bhd
KLSE:1694
|
0.058x |
|
Thien Viet Securities JSC
VN:TVS
|
0.356x |
|
Kc Cottrell
KO:119650
|
-0.341x |
Annual Cash Flow Conversion Efficiency for Guerbet S. A. (2004–2025)
The table below shows the annual cash flow conversion efficiency of Guerbet S. A. from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Guerbet S. A..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €260.08 Million ≈ $304.06 Million |
€61.29 Million ≈ $71.66 Million |
0.236x | +13.62% |
| 2024-12-31 | €391.57 Million ≈ $457.79 Million |
€81.22 Million ≈ $94.95 Million |
0.207x | +185.97% |
| 2023-12-31 | €378.27 Million ≈ $442.24 Million |
€27.44 Million ≈ $32.08 Million |
0.073x | -9.56% |
| 2022-12-31 | €379.57 Million ≈ $443.76 Million |
€30.44 Million ≈ $35.59 Million |
0.080x | -71.99% |
| 2021-12-31 | €405.09 Million ≈ $473.60 Million |
€115.97 Million ≈ $135.58 Million |
0.286x | -12.58% |
| 2020-12-31 | €367.75 Million ≈ $429.94 Million |
€120.43 Million ≈ $140.80 Million |
0.327x | -2.91% |
| 2019-12-31 | €389.19 Million ≈ $455.01 Million |
€131.27 Million ≈ $153.47 Million |
0.337x | +60.82% |
| 2018-12-31 | €366.76 Million ≈ $428.78 Million |
€76.92 Million ≈ $89.93 Million |
0.210x | +28.02% |
| 2017-12-31 | €342.14 Million ≈ $400.00 Million |
€56.05 Million ≈ $65.53 Million |
0.164x | +33.31% |
| 2016-12-31 | €314.80 Million ≈ $368.03 Million |
€38.69 Million ≈ $45.23 Million |
0.123x | -47.13% |
| 2015-12-31 | €282.44 Million ≈ $330.20 Million |
€65.65 Million ≈ $76.75 Million |
0.232x | +0.42% |
| 2014-12-31 | €259.10 Million ≈ $302.92 Million |
€59.98 Million ≈ $70.12 Million |
0.231x | -6.97% |
| 2013-12-31 | €238.26 Million ≈ $278.55 Million |
€59.28 Million ≈ $69.30 Million |
0.249x | +26.10% |
| 2012-12-31 | €226.21 Million ≈ $264.46 Million |
€44.63 Million ≈ $52.18 Million |
0.197x | +2.26% |
| 2011-12-31 | €214.80 Million ≈ $251.12 Million |
€41.44 Million ≈ $48.45 Million |
0.193x | +9.66% |
| 2010-12-31 | €210.52 Million ≈ $246.12 Million |
€37.04 Million ≈ $43.30 Million |
0.176x | -2.95% |
| 2009-12-31 | €205.31 Million ≈ $240.02 Million |
€37.22 Million ≈ $43.51 Million |
0.181x | +6.39% |
| 2008-12-31 | €185.73 Million ≈ $217.13 Million |
€31.65 Million ≈ $37.00 Million |
0.170x | -27.70% |
| 2007-12-31 | €170.96 Million ≈ $199.86 Million |
€40.29 Million ≈ $47.11 Million |
0.236x | +244.21% |
| 2006-12-31 | €152.14 Million ≈ $177.86 Million |
€10.42 Million ≈ $12.18 Million |
0.068x | -76.90% |
| 2005-12-31 | €141.16 Million ≈ $165.03 Million |
€41.84 Million ≈ $48.92 Million |
0.296x | +10.90% |
| 2004-12-31 | €120.21 Million ≈ $140.54 Million |
€32.13 Million ≈ $37.56 Million |
0.267x | -- |
About Guerbet S. A.
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconne… Read more